Pengaruh Modifikasi Pola Hidup Dengan Atau Tanpa Metformin Terhadap Kadar Fetuin-A Pada Penderita Obesitas
45
DAFTAR PUSTAKA
1. Hossain P, Kawar B, El Nahas M. Obesity and Diabetes in developing
world: a growing Chalengge. In : N Engl J Med. 2007; 356:213-15.
2. Sugondo S. Obesitas. Dalam : Buku Ajar Ilmu Penyakit Dalam. Sudoyo
AW, Setiyohadi B, Alwi I, dkk (Eds). Jakarta. Pusat Penerbitan Ilmu
Penyakit Dalam FKUI 2009; 5:3:1973-83.
3. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flagel KM.
Prevalence of overweight and obesity in the United Stated, 1999-2004.
JAMA. 2006; 295:1549-55.
4. Savage DB, Petersen KF, Shulman GI, Disordered Lipid Metabolism and
the Pathogenesis of Insulin Resistance, 2007; 87: 507-20.
5. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Haring HU, et
al, Fetuin-A Induce Cytokine Expression and Suppresses Adiponectin
Production. Plos ONE, 2008; 3:3:1-9.
6. Reinehr T, Roth CL. Fetuin-A and Its Relation to Metabolic Syndrome
and Fatty Liver Disease in Obese Children Before and After Weight loss :
The Journal of Clinical Endocrinology Metabolism 2008; 93:4479-85.
7. Joachim HI, Michael G, Shlipak, Vincent M, Bradenburg, Sadia A, et al,
Association Between Human Fetuin-A and the Metabolic Syndrome :Data
from American Heart Association. 2006;113:1760-67.
8. Molitch ME, Fujimoto W, Hammon RF, Knowler WC. The diabetes
prevention program and its global implications. In: J Am Soc Nephrol;
2003;14:103-7.
9. Ulf G. Bronas, Diane Treat-Jacobson Patricia Painter, Alternative Forms
of Exercise Training Complementary Therapy in the Prevention and
Management of Type 2 Diabetes. Diabetes Spectrum September 21, 2009;
22:4: 220-225.
10. Sumiardji.G. Prediabetes: Apakah perlu diobati? . Dalam : Naskah
Lengkap PIT Ilmu Penyakit Dalam FK USU 2006; 113-5.
Universitas Sumatera Utara
46
11. Diabetes Prevention Program Research Group, Reduction in the Incidence
of Type 2 Diabetes with Lifestyle Intervention or Metformin, The New
England Jounal of Medicine, 2002; 346:6: 393-403.
12. Bray. Medical Consequence of Obesity. In: J Clin Endocrinol Metab;
2004; 89:6: 2583-9.
13. Cavil N, Ells L, Treating adult obesity through lifestyle change
interventions. A briefing paper for commissioners. Oxford: National
obesity Observatory; 2010; 1-18.
14. Sugondo S. Obesitas pada Sindroma Metabolik : Penyebab atau akibat.
Dalam : Naskah lengkap PIT Penyakit Dalam 2005. Jakarta. Pusat
Penerbitan Ilmu Penyakit Dalam FKUI. 2005; 83-6.
15. World Health Organization. Redefining obesity and its treatment: The asia
pacific perspective, 2013.
16. World Health Organization. Obesity Technical Report Series 894, Geneva.
2000.
17. The National Institute of Health. Clinical Guideline on identification,
evaluation and the treatment of overweight and obesity in adult.Obes.Res
2000; 00:4084-9.
18. Stefan N, Haring HU, The Metabolically Benign and Malignant Fatty
Liver, 2011; 60:8: 1-6.
19. Kaushik S, Ser312 Fetuin-A Phosphorilation and Its Association with
Serum Lipids in Metabolic Syndrom, 2008; 1-116.
20. Papizan JB, Phosphorylation of Fetuin-A Physiological Inhibitor of Insulin
Action, Regulated by Insulin and Leptin, 2007; 1-85
21. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, et al:
Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin
resistance and fat accumulation in the liver in humans. Diabetes Care
2006; 29: 853-857
22. Bhattacharya S, Kundu R, Bhattacharya SU, Mechanism of Lipid Insulin
Resistance: An Overview, Endocrine Metab 2012;27:1: 12-19.
23. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Haring HU, Plasma
Fetuin-A Levels and the Risk of Type 2 Diabetes. 2008; 57: 2762-67.
Universitas Sumatera Utara
47
24. Poirier P, Thomas DG, Bray GA, Hong Y, Stern JS, Xavier F, et al,
Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and
Effect of Weight Loss, 2006; 113: 969-76.
25. Brook
RD.Obesity,
weight
loss
and
vascular
function.
In:
Endocrine;2006;29:21-25.
26. Diabetes Prevention Programs Research Group. Reductioan Incidence of
Type 2 Diabetes with Lifestyle Intervention or Metformin. NEJM;2002;
346:6: 393-403
27. Herman WH, Hoerger T, Brandle M, Hicks K, Sorensen S, Zhang P, The
Cost-Effectivenes of Lifestyle Modification or Metformin in Preventing
Type 2 Diabetes in Adults with Impaired Glucose Tolerance, 2005; 142:5;
323-332.
28. Ramachandran A, Shenelata C, Mary S, Mukesh B, Bhaskar VJ, Vijay V
et al. The Indian Diabetes Prevention Programme Shows that Lifestyle
Modification and Metformin Prevent Type 2 Diabetes in Asian Indian
Subjects with Impaired Glucose Tolerance (IDPP-1). Diabetologia;
2006;49: 289-297.
29. Ulf G. Bronas, Diane Treat-Jacobson Patricia Painter, Alternative Forms
of Exercise Training Complementary Therapy in the Prevention and
Management of Type 2 Diabetes. Diabetes Spectrum September 21, 2009;
22:4: 220-225
30. WHO WPR/IASO/IOTF. Redefining Obesity and its treatment. The Asia
– Pasific Perspective. 2000.
31. Bray GA. Drugs Used Clinically to Reduce Body Weight In: Clinical
Obesity in Adult and Children. Kopelmen PG et al (eds). Balackwell
Publishing. 2010;3: 327-338
32. Dahlan
S.
Besar
Sampel
dalam
Penelitian
Kedokteran
dan
Kesehatan.Jakarta.PT Arkans; 2005; 2: 59.
33. Malin SK, Mulya A, Fealy CE, Haus JM, Padagala MR, Huang H, et al,
Fetuin-A linked to improved glucose tolerance after short-term exercise
training in nonalcoholic fatty liver disease. 2013;1:115:7:988-94.
Universitas Sumatera Utara
48
34. PERKENI. Konsensus Pengelolaan Diabetes Melitus Tipe 2 di Indonesia;
Jakarta; 2006
35. Markus A. Neurobiology of obesity. Nat Neurosci. 2005; 8:5: 551-12
36. Vincent HK, Taylor AS, Biomarkers and potential mechanisms of obesityinduced oxidant stress in human, International Journal of Obesity; 2006;
30: 400-18.
37. Ismail NA, Ragab S, Dayem SA, Elbaky AA, Salah N, Hamed M, et al,
Fetuin-A level in obesity: differences in relation to metabolic syndrome
and corellation with clinical and laboratory variable, Arch Med Sci, 2012;
8:5: 826-33.
38. Syahbuddin S. Resistensi insulin dan implikasinya. Naskah lengkap forum
diabetes nasional 4 Padang. 2007; 1-11
39. Donelly JE, Jacobsen DJ, Heelen KS, Seip R, Smith S. The effect of 18
months intermitten vs continue exercise on aerobic capacity, Body weight
and composition. Int Obese; 2000; 24: 566-572.
40. Manaf A. Effect of metformin therapy on plasma adiponectine in obesity
with prediabetes patients. Laporan penelitian. 2008
41. Lindarto D. Pengaruh gaya hidup medik tanpa metformin (PHMTM) dan
pengaruh gaya hidup medik dengan metformin (PHMM) terhadap
parameter chemerin, adiponektin, ADMA, hsCRP dan insulin pada
sindroma metabolik (disertasi). Medan: Universitas Sumatera Utara. 2011
42. Abubakar A, Mabrouk MA, Gerie AB, Dikko AA, Aliyu S, Yusuf T et al.
Relation of body mass index with lipid profile and blood pressure in
healthy female of lower economy group, in Kaduna norther Nigeria.
Asian Journal of Medical Sciences; 2009;1: 94-96
43. Decroli E. Adiponektin: Penatalaksanaan hipertensi pada diabetes.
Naskah lengkap pertemuan ilmiah berkala IX Ilmu Penyaki Dalam
Padang,2008: 81-89
44. Manaf A. A agressive treatment on type 2 diabetes meliitus earlier with
combination therapy. Naskah lengkappertemuanilmiah berkala IX Ilmu
Penyakit Dalam Padang,2008;1-18
Universitas Sumatera Utara
49
45. Chan WB. Management of obesity from lifestyle modification to weight
reduction surgery. The Hongkong Medical Buletin;2010;15: 5-7
46. Tina L, Dumbar JA, Chapman A, et al. Prevention of type 2 diabetes by
lifestyle intervension in an australia primary health care setting: Greather
green triangle. BMC; 2007;7-249
47. Ishibashi A, Ikeda Y, Ohguro T, Kumon Y, Yamanaka S, Takata H, et al,
Serum fetuin-A is an Independent Markers of Insulin resisten in Japanese
Men, J Atheroscler Thromb, 2010; 17:8:925-33. .
48. Brix JM, Stingl H, Holleri F, Schernthaner GH, Kopp HP, Schnernthaner
G, Elevated Fetuin-A Consentration in Morbid Obesity Decrease after
Dramatic Weight Loss, J Clinical Endocrinol Metab 2010; 95:4877-81.
49. Halomoan BS, Pengaruh Pola Hidup Medis dengan atau tanpa Metformin
terhadap kadar Adiponektin pada penderita Obesitas, 2010.
50. Mannuci E, Ognibene A, Cremasco F, Bardni G, Mencucci A, Pierazzuoli
E et al. Effect of metformin on glucogen like peptide 1 (GLP-1) and leptin
levels in obese nondiabetic subjects. Diabetes Care;2001; 24:489-494
51. Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of
initiating insulin and metformin on glycemic control and inflammatory
biomarkers among patients with type 2 diabetes. JAMA;2009; 302:11861194
Universitas Sumatera Utara
DAFTAR PUSTAKA
1. Hossain P, Kawar B, El Nahas M. Obesity and Diabetes in developing
world: a growing Chalengge. In : N Engl J Med. 2007; 356:213-15.
2. Sugondo S. Obesitas. Dalam : Buku Ajar Ilmu Penyakit Dalam. Sudoyo
AW, Setiyohadi B, Alwi I, dkk (Eds). Jakarta. Pusat Penerbitan Ilmu
Penyakit Dalam FKUI 2009; 5:3:1973-83.
3. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flagel KM.
Prevalence of overweight and obesity in the United Stated, 1999-2004.
JAMA. 2006; 295:1549-55.
4. Savage DB, Petersen KF, Shulman GI, Disordered Lipid Metabolism and
the Pathogenesis of Insulin Resistance, 2007; 87: 507-20.
5. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Haring HU, et
al, Fetuin-A Induce Cytokine Expression and Suppresses Adiponectin
Production. Plos ONE, 2008; 3:3:1-9.
6. Reinehr T, Roth CL. Fetuin-A and Its Relation to Metabolic Syndrome
and Fatty Liver Disease in Obese Children Before and After Weight loss :
The Journal of Clinical Endocrinology Metabolism 2008; 93:4479-85.
7. Joachim HI, Michael G, Shlipak, Vincent M, Bradenburg, Sadia A, et al,
Association Between Human Fetuin-A and the Metabolic Syndrome :Data
from American Heart Association. 2006;113:1760-67.
8. Molitch ME, Fujimoto W, Hammon RF, Knowler WC. The diabetes
prevention program and its global implications. In: J Am Soc Nephrol;
2003;14:103-7.
9. Ulf G. Bronas, Diane Treat-Jacobson Patricia Painter, Alternative Forms
of Exercise Training Complementary Therapy in the Prevention and
Management of Type 2 Diabetes. Diabetes Spectrum September 21, 2009;
22:4: 220-225.
10. Sumiardji.G. Prediabetes: Apakah perlu diobati? . Dalam : Naskah
Lengkap PIT Ilmu Penyakit Dalam FK USU 2006; 113-5.
Universitas Sumatera Utara
46
11. Diabetes Prevention Program Research Group, Reduction in the Incidence
of Type 2 Diabetes with Lifestyle Intervention or Metformin, The New
England Jounal of Medicine, 2002; 346:6: 393-403.
12. Bray. Medical Consequence of Obesity. In: J Clin Endocrinol Metab;
2004; 89:6: 2583-9.
13. Cavil N, Ells L, Treating adult obesity through lifestyle change
interventions. A briefing paper for commissioners. Oxford: National
obesity Observatory; 2010; 1-18.
14. Sugondo S. Obesitas pada Sindroma Metabolik : Penyebab atau akibat.
Dalam : Naskah lengkap PIT Penyakit Dalam 2005. Jakarta. Pusat
Penerbitan Ilmu Penyakit Dalam FKUI. 2005; 83-6.
15. World Health Organization. Redefining obesity and its treatment: The asia
pacific perspective, 2013.
16. World Health Organization. Obesity Technical Report Series 894, Geneva.
2000.
17. The National Institute of Health. Clinical Guideline on identification,
evaluation and the treatment of overweight and obesity in adult.Obes.Res
2000; 00:4084-9.
18. Stefan N, Haring HU, The Metabolically Benign and Malignant Fatty
Liver, 2011; 60:8: 1-6.
19. Kaushik S, Ser312 Fetuin-A Phosphorilation and Its Association with
Serum Lipids in Metabolic Syndrom, 2008; 1-116.
20. Papizan JB, Phosphorylation of Fetuin-A Physiological Inhibitor of Insulin
Action, Regulated by Insulin and Leptin, 2007; 1-85
21. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, et al:
Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin
resistance and fat accumulation in the liver in humans. Diabetes Care
2006; 29: 853-857
22. Bhattacharya S, Kundu R, Bhattacharya SU, Mechanism of Lipid Insulin
Resistance: An Overview, Endocrine Metab 2012;27:1: 12-19.
23. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Haring HU, Plasma
Fetuin-A Levels and the Risk of Type 2 Diabetes. 2008; 57: 2762-67.
Universitas Sumatera Utara
47
24. Poirier P, Thomas DG, Bray GA, Hong Y, Stern JS, Xavier F, et al,
Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and
Effect of Weight Loss, 2006; 113: 969-76.
25. Brook
RD.Obesity,
weight
loss
and
vascular
function.
In:
Endocrine;2006;29:21-25.
26. Diabetes Prevention Programs Research Group. Reductioan Incidence of
Type 2 Diabetes with Lifestyle Intervention or Metformin. NEJM;2002;
346:6: 393-403
27. Herman WH, Hoerger T, Brandle M, Hicks K, Sorensen S, Zhang P, The
Cost-Effectivenes of Lifestyle Modification or Metformin in Preventing
Type 2 Diabetes in Adults with Impaired Glucose Tolerance, 2005; 142:5;
323-332.
28. Ramachandran A, Shenelata C, Mary S, Mukesh B, Bhaskar VJ, Vijay V
et al. The Indian Diabetes Prevention Programme Shows that Lifestyle
Modification and Metformin Prevent Type 2 Diabetes in Asian Indian
Subjects with Impaired Glucose Tolerance (IDPP-1). Diabetologia;
2006;49: 289-297.
29. Ulf G. Bronas, Diane Treat-Jacobson Patricia Painter, Alternative Forms
of Exercise Training Complementary Therapy in the Prevention and
Management of Type 2 Diabetes. Diabetes Spectrum September 21, 2009;
22:4: 220-225
30. WHO WPR/IASO/IOTF. Redefining Obesity and its treatment. The Asia
– Pasific Perspective. 2000.
31. Bray GA. Drugs Used Clinically to Reduce Body Weight In: Clinical
Obesity in Adult and Children. Kopelmen PG et al (eds). Balackwell
Publishing. 2010;3: 327-338
32. Dahlan
S.
Besar
Sampel
dalam
Penelitian
Kedokteran
dan
Kesehatan.Jakarta.PT Arkans; 2005; 2: 59.
33. Malin SK, Mulya A, Fealy CE, Haus JM, Padagala MR, Huang H, et al,
Fetuin-A linked to improved glucose tolerance after short-term exercise
training in nonalcoholic fatty liver disease. 2013;1:115:7:988-94.
Universitas Sumatera Utara
48
34. PERKENI. Konsensus Pengelolaan Diabetes Melitus Tipe 2 di Indonesia;
Jakarta; 2006
35. Markus A. Neurobiology of obesity. Nat Neurosci. 2005; 8:5: 551-12
36. Vincent HK, Taylor AS, Biomarkers and potential mechanisms of obesityinduced oxidant stress in human, International Journal of Obesity; 2006;
30: 400-18.
37. Ismail NA, Ragab S, Dayem SA, Elbaky AA, Salah N, Hamed M, et al,
Fetuin-A level in obesity: differences in relation to metabolic syndrome
and corellation with clinical and laboratory variable, Arch Med Sci, 2012;
8:5: 826-33.
38. Syahbuddin S. Resistensi insulin dan implikasinya. Naskah lengkap forum
diabetes nasional 4 Padang. 2007; 1-11
39. Donelly JE, Jacobsen DJ, Heelen KS, Seip R, Smith S. The effect of 18
months intermitten vs continue exercise on aerobic capacity, Body weight
and composition. Int Obese; 2000; 24: 566-572.
40. Manaf A. Effect of metformin therapy on plasma adiponectine in obesity
with prediabetes patients. Laporan penelitian. 2008
41. Lindarto D. Pengaruh gaya hidup medik tanpa metformin (PHMTM) dan
pengaruh gaya hidup medik dengan metformin (PHMM) terhadap
parameter chemerin, adiponektin, ADMA, hsCRP dan insulin pada
sindroma metabolik (disertasi). Medan: Universitas Sumatera Utara. 2011
42. Abubakar A, Mabrouk MA, Gerie AB, Dikko AA, Aliyu S, Yusuf T et al.
Relation of body mass index with lipid profile and blood pressure in
healthy female of lower economy group, in Kaduna norther Nigeria.
Asian Journal of Medical Sciences; 2009;1: 94-96
43. Decroli E. Adiponektin: Penatalaksanaan hipertensi pada diabetes.
Naskah lengkap pertemuan ilmiah berkala IX Ilmu Penyaki Dalam
Padang,2008: 81-89
44. Manaf A. A agressive treatment on type 2 diabetes meliitus earlier with
combination therapy. Naskah lengkappertemuanilmiah berkala IX Ilmu
Penyakit Dalam Padang,2008;1-18
Universitas Sumatera Utara
49
45. Chan WB. Management of obesity from lifestyle modification to weight
reduction surgery. The Hongkong Medical Buletin;2010;15: 5-7
46. Tina L, Dumbar JA, Chapman A, et al. Prevention of type 2 diabetes by
lifestyle intervension in an australia primary health care setting: Greather
green triangle. BMC; 2007;7-249
47. Ishibashi A, Ikeda Y, Ohguro T, Kumon Y, Yamanaka S, Takata H, et al,
Serum fetuin-A is an Independent Markers of Insulin resisten in Japanese
Men, J Atheroscler Thromb, 2010; 17:8:925-33. .
48. Brix JM, Stingl H, Holleri F, Schernthaner GH, Kopp HP, Schnernthaner
G, Elevated Fetuin-A Consentration in Morbid Obesity Decrease after
Dramatic Weight Loss, J Clinical Endocrinol Metab 2010; 95:4877-81.
49. Halomoan BS, Pengaruh Pola Hidup Medis dengan atau tanpa Metformin
terhadap kadar Adiponektin pada penderita Obesitas, 2010.
50. Mannuci E, Ognibene A, Cremasco F, Bardni G, Mencucci A, Pierazzuoli
E et al. Effect of metformin on glucogen like peptide 1 (GLP-1) and leptin
levels in obese nondiabetic subjects. Diabetes Care;2001; 24:489-494
51. Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. Effects of
initiating insulin and metformin on glycemic control and inflammatory
biomarkers among patients with type 2 diabetes. JAMA;2009; 302:11861194
Universitas Sumatera Utara